Equine cytochrome P450 2C92: cDNA cloning, expression and initial characterization

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Substantial gaps exist in our knowledge of the metabolic clearance of therapeutic agents in horses. Accordingly, a cytochrome P450 monooxygenase in the 2C family was cloned from an equine liver, sequenced and expressed in a baculovirus expression system. Catalytic activities of the recombinant protein were measured with a number of substrates. The protein, assigned CYP2C92, displayed optimal catalytic activity with diclofenac using molar ratios of CYP2C92 to NADPH CYP450 reductase of 1:18. Addition of cytochrome b5 to diclofenac incubations had no significant effect on metabolic turnover. CYP2C92 catalyzed diclofenac metabolism was 20-fold slower than the human counterpart, CYP2C9. CYP2C92 demonstrated comparable tolbutamide and (S)-warfarin hydroxylase activity compared to CYP2C9, upon addition of b5 to the reactions. The results of this study demonstrate substantial interspecies differences in metabolism of substrates by CYP2C orthologues in the horse and human and support the need to fully characterize this enzyme system in equids.

Original languageEnglish (US)
Pages (from-to)49-55
Number of pages7
JournalArchives of Biochemistry and Biophysics
Volume485
Issue number1
DOIs
StatePublished - May 1 2009

Fingerprint

Diclofenac
Cloning
Cytochrome P-450 Enzyme System
Horses
Organism Cloning
Complementary DNA
Mixed Function Oxygenases
Metabolism
Catalyst activity
Cytochromes b5
Tolbutamide
Baculoviridae
Warfarin
Substrates
NADP
Recombinant Proteins
Liver
Oxidoreductases
Enzymes
Proteins

Keywords

  • CYP2C
  • CYP450
  • Diclofenac
  • Horse
  • Mephenytoin
  • Phase I metabolism
  • Tolbutamide
  • Warfarin

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Equine cytochrome P450 2C92 : cDNA cloning, expression and initial characterization. / DiMaio Knych, H. K.; DeStefano Shields, C.; Buckpitt, A. R.; Stanley, S. D.

In: Archives of Biochemistry and Biophysics, Vol. 485, No. 1, 01.05.2009, p. 49-55.

Research output: Contribution to journalArticle

@article{fb33e85d86984a35b6ae08312eb43e72,
title = "Equine cytochrome P450 2C92: cDNA cloning, expression and initial characterization",
abstract = "Substantial gaps exist in our knowledge of the metabolic clearance of therapeutic agents in horses. Accordingly, a cytochrome P450 monooxygenase in the 2C family was cloned from an equine liver, sequenced and expressed in a baculovirus expression system. Catalytic activities of the recombinant protein were measured with a number of substrates. The protein, assigned CYP2C92, displayed optimal catalytic activity with diclofenac using molar ratios of CYP2C92 to NADPH CYP450 reductase of 1:18. Addition of cytochrome b5 to diclofenac incubations had no significant effect on metabolic turnover. CYP2C92 catalyzed diclofenac metabolism was 20-fold slower than the human counterpart, CYP2C9. CYP2C92 demonstrated comparable tolbutamide and (S)-warfarin hydroxylase activity compared to CYP2C9, upon addition of b5 to the reactions. The results of this study demonstrate substantial interspecies differences in metabolism of substrates by CYP2C orthologues in the horse and human and support the need to fully characterize this enzyme system in equids.",
keywords = "CYP2C, CYP450, Diclofenac, Horse, Mephenytoin, Phase I metabolism, Tolbutamide, Warfarin",
author = "{DiMaio Knych}, {H. K.} and {DeStefano Shields}, C. and Buckpitt, {A. R.} and Stanley, {S. D.}",
year = "2009",
month = "5",
day = "1",
doi = "10.1016/j.abb.2009.02.009",
language = "English (US)",
volume = "485",
pages = "49--55",
journal = "Archives of Biochemistry and Biophysics",
issn = "0003-9861",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Equine cytochrome P450 2C92

T2 - cDNA cloning, expression and initial characterization

AU - DiMaio Knych, H. K.

AU - DeStefano Shields, C.

AU - Buckpitt, A. R.

AU - Stanley, S. D.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Substantial gaps exist in our knowledge of the metabolic clearance of therapeutic agents in horses. Accordingly, a cytochrome P450 monooxygenase in the 2C family was cloned from an equine liver, sequenced and expressed in a baculovirus expression system. Catalytic activities of the recombinant protein were measured with a number of substrates. The protein, assigned CYP2C92, displayed optimal catalytic activity with diclofenac using molar ratios of CYP2C92 to NADPH CYP450 reductase of 1:18. Addition of cytochrome b5 to diclofenac incubations had no significant effect on metabolic turnover. CYP2C92 catalyzed diclofenac metabolism was 20-fold slower than the human counterpart, CYP2C9. CYP2C92 demonstrated comparable tolbutamide and (S)-warfarin hydroxylase activity compared to CYP2C9, upon addition of b5 to the reactions. The results of this study demonstrate substantial interspecies differences in metabolism of substrates by CYP2C orthologues in the horse and human and support the need to fully characterize this enzyme system in equids.

AB - Substantial gaps exist in our knowledge of the metabolic clearance of therapeutic agents in horses. Accordingly, a cytochrome P450 monooxygenase in the 2C family was cloned from an equine liver, sequenced and expressed in a baculovirus expression system. Catalytic activities of the recombinant protein were measured with a number of substrates. The protein, assigned CYP2C92, displayed optimal catalytic activity with diclofenac using molar ratios of CYP2C92 to NADPH CYP450 reductase of 1:18. Addition of cytochrome b5 to diclofenac incubations had no significant effect on metabolic turnover. CYP2C92 catalyzed diclofenac metabolism was 20-fold slower than the human counterpart, CYP2C9. CYP2C92 demonstrated comparable tolbutamide and (S)-warfarin hydroxylase activity compared to CYP2C9, upon addition of b5 to the reactions. The results of this study demonstrate substantial interspecies differences in metabolism of substrates by CYP2C orthologues in the horse and human and support the need to fully characterize this enzyme system in equids.

KW - CYP2C

KW - CYP450

KW - Diclofenac

KW - Horse

KW - Mephenytoin

KW - Phase I metabolism

KW - Tolbutamide

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=64549119690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64549119690&partnerID=8YFLogxK

U2 - 10.1016/j.abb.2009.02.009

DO - 10.1016/j.abb.2009.02.009

M3 - Article

C2 - 19245785

AN - SCOPUS:64549119690

VL - 485

SP - 49

EP - 55

JO - Archives of Biochemistry and Biophysics

JF - Archives of Biochemistry and Biophysics

SN - 0003-9861

IS - 1

ER -